[go: up one dir, main page]

PE20130496A1 - Tratamiento de artritis por lupus usando laquinimod - Google Patents

Tratamiento de artritis por lupus usando laquinimod

Info

Publication number
PE20130496A1
PE20130496A1 PE2012001382A PE2012001382A PE20130496A1 PE 20130496 A1 PE20130496 A1 PE 20130496A1 PE 2012001382 A PE2012001382 A PE 2012001382A PE 2012001382 A PE2012001382 A PE 2012001382A PE 20130496 A1 PE20130496 A1 PE 20130496A1
Authority
PE
Peru
Prior art keywords
laquinimod
lupus arthritis
arthritis treatment
treatment
active lupus
Prior art date
Application number
PE2012001382A
Other languages
English (en)
Inventor
Asi Haviv
Nora Tarcic
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130496(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PE20130496A1 publication Critical patent/PE20130496A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UN METODO DE TRATAMIENTO DE ARTRITIS POR LUPUS ACTIVO CON LAQUINIMOD QUE CONSISTE EN ADMINISTRAR PERIODICAMENTE POR AL MENOS 12 SEMANAS UNA CANTIDAD DE 0.5-1.0 mg/dia DE LAQUINIMOD SODICO EN FORMA ORAL, CONJUNTAMENTE CON CORTICOIDES, INMUNOSUPRESORES, FARMACOS ANTIPALUDICOS, ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO METODO REDUCE LOS SINTOMAS DE ARTRITIS POR LUPUS ACTIVO COMO HINCHAZON DE ARTICULACIONES.
PE2012001382A 2010-03-03 2011-03-02 Tratamiento de artritis por lupus usando laquinimod PE20130496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33935510P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
PE20130496A1 true PE20130496A1 (es) 2013-05-08

Family

ID=44531530

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001382A PE20130496A1 (es) 2010-03-03 2011-03-02 Tratamiento de artritis por lupus usando laquinimod

Country Status (21)

Country Link
US (4) US20110217295A1 (es)
EP (1) EP2542080B1 (es)
JP (2) JP2013521305A (es)
KR (1) KR20130036217A (es)
CN (1) CN102781239B (es)
AU (1) AU2011223702B2 (es)
BR (1) BR112012022064A2 (es)
CA (1) CA2791711A1 (es)
CL (1) CL2012002422A1 (es)
CO (1) CO6630086A2 (es)
EA (1) EA201290859A1 (es)
ES (1) ES2601819T3 (es)
MX (1) MX342001B (es)
NZ (1) NZ602512A (es)
PE (1) PE20130496A1 (es)
PH (1) PH12012501741A1 (es)
PL (1) PL2542080T3 (es)
PT (1) PT2542080T (es)
SG (2) SG183515A1 (es)
WO (1) WO2011109536A1 (es)
ZA (1) ZA201207125B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1937642T1 (sl) * 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
PL2234485T3 (pl) 2007-12-20 2014-06-30 Teva Pharma Stabilne preparaty lakwinimodu
UA104005C2 (ru) * 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
SG176840A1 (en) * 2009-06-19 2012-02-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
EP2467372B1 (en) 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
ES2558556T3 (es) * 2010-03-03 2016-02-05 Teva Pharmaceutical Industries Ltd. Tratamiento de nefritis lúpica usando laquinimod
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
ES2601819T3 (es) * 2010-03-03 2017-02-16 Teva Pharmaceutical Industries Ltd. Tratamiento de la artritis lúpica usando laquinimod
EA025377B1 (ru) 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
JP2014530821A (ja) 2011-10-12 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
CA2862865A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf.alpha. therapy
EP2744498A4 (en) 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
HK1220125A1 (zh) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. 拉喹莫德的透皮配方
MX2015011627A (es) 2013-03-14 2016-05-16 Teva Pharma Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos.
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
RS51019B (sr) * 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
EP1365794A2 (en) * 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
AU2004251754A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
AU2005231467A1 (en) * 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
WO2006029036A2 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
CA2626082C (en) * 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
SI1937642T1 (sl) * 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
EP1951674B1 (en) * 2005-10-26 2011-11-23 Merck Serono SA Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
WO2007100763A2 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
PT2676967T (pt) * 2006-02-28 2019-09-27 Biogen Ma Inc Métodos para tratamento de doenças inflamatórias e autoimunes com natalizumab
CA2644110A1 (en) * 2006-03-03 2007-09-13 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2007139887A2 (en) * 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
AU2007258366B2 (en) * 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
US20080090897A1 (en) * 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
JP5468001B2 (ja) * 2007-07-11 2014-04-09 メディシノバ，インコーポレーテッド イブジラストを含む進行性神経変性疾患の処置用医薬組成物
PL2234485T3 (pl) * 2007-12-20 2014-06-30 Teva Pharma Stabilne preparaty lakwinimodu
UA104005C2 (ru) * 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
SG176840A1 (en) * 2009-06-19 2012-02-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
EP2467372B1 (en) * 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
ES2601819T3 (es) * 2010-03-03 2017-02-16 Teva Pharmaceutical Industries Ltd. Tratamiento de la artritis lúpica usando laquinimod
EA025377B1 (ru) * 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
MX2015011627A (es) * 2013-03-14 2016-05-16 Teva Pharma Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos.

Also Published As

Publication number Publication date
CO6630086A2 (es) 2013-03-01
JP2016196473A (ja) 2016-11-24
US20150086549A1 (en) 2015-03-26
EP2542080A1 (en) 2013-01-09
BR112012022064A2 (pt) 2015-09-08
PH12012501741A1 (en) 2012-11-12
HK1177876A1 (zh) 2013-08-30
CN102781239A (zh) 2012-11-14
WO2011109536A1 (en) 2011-09-09
PT2542080T (pt) 2016-11-16
NZ602512A (en) 2014-07-25
CN102781239B (zh) 2015-01-21
EP2542080B1 (en) 2016-08-31
CA2791711A1 (en) 2011-09-09
US20130184310A1 (en) 2013-07-18
SG10201501539SA (en) 2015-04-29
EP2542080A4 (en) 2013-07-17
US20160213663A1 (en) 2016-07-28
KR20130036217A (ko) 2013-04-11
PL2542080T3 (pl) 2017-02-28
US20110217295A1 (en) 2011-09-08
JP2013521305A (ja) 2013-06-10
MX342001B (es) 2016-09-09
AU2011223702A1 (en) 2012-10-25
SG183515A1 (en) 2012-10-30
AU2011223702B2 (en) 2016-07-14
MX2012010071A (es) 2012-10-03
ES2601819T3 (es) 2017-02-16
CL2012002422A1 (es) 2012-12-21
ZA201207125B (en) 2014-06-25
EA201290859A1 (ru) 2013-04-30

Similar Documents

Publication Publication Date Title
PE20130496A1 (es) Tratamiento de artritis por lupus usando laquinimod
PE20130690A1 (es) Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
PE20120791A1 (es) Composiciones y metodos para terapia prolongada con aminopiridinas
BR112012016543A2 (pt) Tratamento com vb-201
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
TN2015000135A1 (en) Modified release formulations for oprozomib
CY1121973T1 (el) Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
AR083095A1 (es) Cocristal de aprepitant l-prolina y composicion farmaceutica
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
IN2014MN01806A (es)
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.

Legal Events

Date Code Title Description
FC Refusal